TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: Kantarjian et al.’s study revealed that CML patients with imatinib resistance achieved 40% and 28% cytogenic response and molecular response respectively after switching to nilotinib therapy [28], which correspond to our findings since the hematological profile and p53 activation were better in nilotinib-treated patients than imatinib-treated patients.